<DOC>
	<DOCNO>NCT01156532</DOCNO>
	<brief_summary>Adalimumab recently authorize active psoriasis Peru local experience low . The aim study obtain Peruvian data clinical effectiveness impact health-related quality life use adalimumab participant chronic plaque psoriasis comply dose monitoring recommendation local approve label .</brief_summary>
	<brief_title>Clinical Effectiveness Impact Health-related Quality Life Peruvian Patients With Psoriasis After 16 Weeks Adalimumab Therapy</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Participants moderate severe chronic plaque psoriasis define Psoriasis Area Severity Index ( PASI ) ≥ 10 body surface area ≥ 10 % without psoriatic arthritis , adalimumab therapy indication candidate systemic therapy phototherapy systemic therapy medically less appropriate Participant capable willing give write informed consent comply requirement study protocol Participants enrol treated accordance local product label Participants enrol another study clinical trial History hepatitis B infection History neurologic symptom suggestive central nervous system demyelinate disease History cancer lymphoproliferative disease ( successfully treat nonmelanoma skin cancer localize carcinoma situ cervix ) Active tuberculosis infection initiate adalimumab treatment latent tuberculosis infection able take complete prophylactic treatment Pregnant lactate female , demonstrate pregnancy test enter study willing use contraceptive method Use another antitumoral necrosis factor previously History congestive heart failure Any condition accord criterion participate investigator represent obstacle study conduction and/or subject participant unacceptable risk Participants active infection include chronic localized infection infection control History sensitivity latex Participants receive concomitant phototherapy systemic therapy adalimumab therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>adalimumab therapy</keyword>
	<keyword>Psoriasis</keyword>
	<keyword>observational study</keyword>
</DOC>